Family Connections for Caregivers of People With Suicidal Behavior

December 5, 2022 updated by: University of Valencia

Family Connections for Caregivers of People With Suicidal Behavior: Study Protocol of a Randomized Control Trial.

The aim of our study is to verify the efficacy of the Family Connections intervention for relatives of people diagnosed with suicidal behavior disorder in a randomized control trial with a Spanish participants.

Study Overview

Detailed Description

Family members of people who have attempted suicide feel guilty, afraid, hopeless, depression and anxiety. The needs of family members of people with suicide attempts are not adequately addressed in the current treatments for people with suicide attempts. Therefore, it is necessary to help the relatives of people with suicidal behaviors to reduce the discomfort and burden they experience by giving them information and skills to improve their relationship with patients. Family Connections (FC) is a program that has been shown to be effective in reducing burden, depression, and anxiety, and in increasing dominance and validating behaviors in relatives of people with borderline personality disorder. However, there are no Randomized Control Trials that demonstrate the efficacy of FC program in patients with suicide attempts. In a previous study, FC was adapted in an open trial with relatives of people who had attempted suicide. The results of this pilot study suggest that the FC program tailored to relatives of patients with suicide attempts may be effective in improving well-being and reducing the burden of illness in relatives.

Our research team adapted FC for relatives of people diagnosed with suicidal behavior disorder (SBD) for delivery in the Spanish population. The FC-SCD program contains 12 two-hour sessions held once a week. The first aim is to verify the efficacy of the FC intervention for relatives of people diagnosed with SBD in a randomized control trial with a Spanish sample of participants from mental health services. The second objective is to analyze the feasibility and acceptance of FC-SBD in relatives. The third aim is to analyze whether the changes produced in the psychological variables in the relatives after the intervention are related to changes in the psychological variables of the patients. This paper presents the study protocol. The study design consists of a two-arm randomized controlled trial, there will be two conditions: Family Connections (FC-SBD) or Treatment as usual optimized (TAU-O). Participants will be relatives of patients who meet DSM-5 criteria for SBD. The caregivers' primary outcome measures will be the BAS. Secondary outcomes will be DASS-21, FES, DERS, QoL. The patient's primary outcome measures will be the INQ, PHQ-9, OASIS, VIRS, LUMP. Participants will be assessed at pretreatment, post-treatment, and 6-month follow-up. The intention-to-treat principle will be used when analyzing data, using mixed-effects models with full information and maximum likelihood estimation.

Study Type

Interventional

Enrollment (Actual)

124

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Valencia, Spain, 46010
        • University of Valencia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Being a caregiver of one patient with a diagnosis of Suicide Behavior Disorder
  • Understand spoken and written Spanish;
  • Signing the informed consent.

Exclusion Criteria:

  • The presence of a diagnosis of severe mental disorder in the caregivers as: Psychosis, schizophrenia, substance dependence, or high suicide ideation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Family Connections Protocol for Relatives of Patients with SBD.

The intervention lasts three months and includes 12 sessions with a weekly two-hour group format. The FC program is divided into six modules:

Module 1: Up-to-date information and research on suicide (Epidemiology, frequency, Risk factors, protective factors).

Module 2: Psychoeducation on the development of suicide, explanatory theories, available treatments, comorbidity.

Module 3: Emotional regulation skills, skills of acceptance, validation, approach, awareness, and to decrease emotional reactivity.

Module 4: Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).

Module 5: Communication skills and effective self-expression. Module 6: Problem management and making safe plans for crisis management.

Family Connections is a Dialectical Behavioral Therapy. All the modules include practice exercises, video viewing, and homework assignments. In addition, throughout the program, with the aim of increasing social support, the FC-SBD program provides a forum where participants can stay in touch and share common problems and solutions.
Active Comparator: Treatment as Usual Optimized Protocol (TAU-O).

Family members in this condition will continue to receive their treatment as usual in their care center of reference. In addition, we will optimize the treatment based on the recommendations of the international guidelines for the treatment of suicide. There will be one three-hour session in group format with the following component:

Module 1: Updated information and research on suicide (Epidemiology, frequency, Risk factors, protective factors). Psychoeducation on the development of Suicide, Explanatory theories. Available treatments, and comorbidity.

Participants will receive the usual treatment in their mental health service and will also receive a psychoeducation session of approximately 3 hours where the predictive and protective factors of suicidal behavior will be explained.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Burden assessment scale (BAS)
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
This 19-item scale assesses two dimensions of caregiver burden of a loved one's illness (objective and subjective) in the past six months. The items are rated on a 4-point Likert scale (1-4), where higher scores indicate higher levels of illness burden. The psychometric properties of this scale are adequate, with an internal reliability between .89 and .91 and adequate validity.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Family empowerment scale (FES)
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
This scale has a total of 34 items. It is composed of three subscales referring to attitudes, knowledge, and behaviors related to (1) Family, (2) the Service System, and (3) Community Participation. The items are rated on a Likert scale (1-5), where higher scores show greater feelings of empowerment. Both the validity and reliability of this scale are adequate, and the internal consistency of the subscales shows coefficients between α = .87 and α =.88.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Depression, anxiety, and stress scale (DASS-21)
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
We have used the short, validated Spanish version with 21 items on the frequency of negative emotional symptoms in the past week. The items are rated on a Likert scale (0-3) where the higher the score, the higher the frequency of symptoms of depression, anxiety, and/or stress. The internal consistency of the scale was excellent, with Cronbach's alphas for the DASS-21 subscales: Depression (α = .94), Anxiety (α = .87) and Stress (α = .91)
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Difficulties in emotion regulation scale - Spanish version
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
We used the Spanish validation containing 28 items. This questionnaire is divided into five subscales: (1) Lack of emotional control, (2) Life interference, (3) Emotional inattention, (4) Emotional confusion, and (5) Emotional rejection. The items are rated on a Likert scale (1-5) where higher scores indicate greater difficulty in regulating emotions. Psychometric properties are excellent, with an internal consistency of α = .93 and test-retest reliability of pl = .74, p < .001
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Quality of life index-Spanish version (QLI-Sp)
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
It consists of a 10-item index of perceived quality of life. It refers to physical and emotional well-being, functioning at work, satisfaction with personal relationships and self-independence, support in the community and from an emotional point of view, spiritual well-being, and perceived overall quality of life. The items are rated on a Likert scale (0-10) where higher scores indicate higher perceived quality of life. The psychometric properties are good for both internal consistency (α = .89) and test-retest reliability (r = 0.87).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Opinion and Expectations of Treatment Scale (OTSM)
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention
This scale was designed and developed by members of the research team and constructed from an adaptation of another opinion and expectations questionnaire [49]. The constructs this scale assesses are: opinion, acceptance and satisfaction with the skills training program, and the changes in the participants after the completion of each module. The questions refer to the rationale for the intervention, recommendation of the program, satisfaction with the program, usefulness and expectations of the skills training. The items are rated on a Likert-type scale ranging from 0 "Not at all" to 10 "Very much".
Changes will be assessed from pre-treatment to immediately after the intervention
Register of critical incidents with the family member with SBD
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
his register was developed ad hoc for this study. The questions recorded are the following: frequency of suicide attempts in the past six months, number of days of self-harm in the past six months, number of episodes of verbal/physical violence with caregivers in the past six months; frequency of visits to the psychiatric emergency room in the past six months, frequency of therapy sessions conducted out of schedule in the past six months (face-to-face, phone calls, etc.).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Register of critical incidents with the patient member with SBD
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
This register was developed ad hoc for this study. The questions recorded are the following: frequency of suicide attempts in the past six months, number of days of self-harm in the past six months, number of episodes of verbal/physical violence with caregivers in the past six months; frequency of visits to the psychiatric emergency room in the past six months, frequency of therapy sessions conducted out of schedule in the past six months (face-to-face, phone calls, etc.).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Interpersonal Needs Questionnaire (INQ)
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
We use the Spanish version of this 15-item questionnaire that assesses the degree of dissatisfaction with their need to belong (frustrated belonging) and the degree to which they perceive themselves as a burden to others (perceived burden). The items are rated on a Likert-type scale (1-7) where higher scores indicate higher levels of frustrated belonging and perceived burden to others. Psychometric properties were good: scale reliability was very good (perceived burden, α = 0.96; and frustrated belonging, α = 0.78).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Patient Health Questionnaire (PHQ-9)
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
It consists of a nine-item questionnaire that assesses depressive symptoms in the past two weeks. Specifically, it includes the DSM-IV diagnostic criteria A for major depressive disorder (American Psychiatric Association, 2000). The items are rated on a Likert scale (0-3) where higher scores indicate higher frequency of depressive symptoms. The severity of depression on this questionnaire is measured through the total score, which can be categorized as none or minimal, mild, moderate, moderately severe, and severe. Validity has been adequate, with a sensitivity of 88% and a specificity of 88% for major depression
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Overall Anxiety Severity and Impairment Scale (OASIS
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
We use the Spanish version of this questionnaire, which consists of a five-item instrument that assesses the frequency and intensity of anxiety symptoms in the past week. In addition, it measures interference in work and academic, social, and daily life domains, as well as avoidance behaviors. The items are rated on a Likert-type scale (0-4). The psychometric properties are good in terms of internal consistency (α= 0.86), convergent and discriminant validity, and sensitivity to change (α= 0.86).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Validating and Invalidating Responses Scale (VIRS)
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
It consists of a 16-item scale on the validation and invalidation of family members' responses about their loved ones. It is divided into two subscales (validation and invalidation), and the items are rated on a Likert scale (0-4) where higher scores indicate higher perceived validation or higher perceived invalidation (depending on the subscale).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
Lum Emotional Availability of Parents
Time Frame: Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.
This 15-item questionnaire measures the perceived emotional availability of primary caregivers. The items are rated on a Likert scale (1-6) where higher scores indicate greater emotional availability of caregivers. Psychometric properties were excellent for both subscales (mother, α = .9; and father, α = .93). In addition, test-retest reliability was also adequate for the mother's subscale (r = .92) and the father's subscale (r = .85).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 6-month follow-up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Isabel Fernández Felipe, PhDStudent, Universitat Jaume I
  • Principal Investigator: Sara Fonseca, PhDStudent, University of Valencia
  • Principal Investigator: Sandra Perez, PhD, Universitat de Valencia
  • Principal Investigator: Rosa Baños, PhD, Universitat de Valencia
  • Principal Investigator: Cristina Botella Arbona, PhD, Universitat Jaume I
  • Principal Investigator: Joaquin Garcia-Alandete, PhD, Universitat de Valencia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 15, 2021

Primary Completion (Anticipated)

April 1, 2023

Study Completion (Anticipated)

April 1, 2023

Study Registration Dates

First Submitted

December 1, 2021

First Submitted That Met QC Criteria

December 1, 2021

First Posted (Actual)

December 15, 2021

Study Record Updates

Last Update Posted (Estimate)

December 6, 2022

Last Update Submitted That Met QC Criteria

December 5, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Individual participant data will be available after deidentification

IPD Sharing Time Frame

The data will be available immediately following publication

IPD Sharing Access Criteria

The data will be available to anyone who wishes to access them.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Clinical Study Report (CSR)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Relatives

Clinical Trials on Family Connections Protocol for Relatives of Patients with SBD.

3
Subscribe